三個皮匠報告
政策庫
new
付費
搜索

GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據-行業數據

GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據
使用GV-971 36周后ADAS-Cog12評分較安慰劑組改善-2.54分（-2.70 vs -0.16）；在MMSE評分20~26分、15~19分、11~14分的3個亞組中，用藥36周后GV-971組ADAS-Cog12評分改善分別為-1.66（-2.97 vs -1.31）、-2.96（-2.23 vs +0.73）、-4.55（-2.65vs +1.90）。
行業數據 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?741KB 圖片尺寸：3757*983
同報告圖片
 / 47
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第1頁
fCBWaXNpdHMgKHdlZWtzKSB8IFBsYWNlYm8gfCBHVi05NzEgfAp8LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS18LS0tLS0tLS18CnwgMCAgICAgICAgICAgICAgfCAtMi4wNCAgIHwgLTEuNDIgIHwKfCA0ICAgICAgICAgICAgICB8IC0yLjMyICAgfCAtMS43MCAgfAp8IDggICAgICAgICAgICAgIHwgLTIuMTkgICB8IC0xLjUwICB8CnwgMTIgICAgICAgICAgICAgfCAtMi43MCAgIHwgLTEuMTYgIHwKCui1hOaWmeadpea6kO+8mkFsemhlaW1lcidzIFJlc2VhcmNoICYgVGhlcmFweSwgZG9pOiAxMC4xMTg2L3MxMzE5NS0wMjEtMDA3OTUtNywg5Zu95L+h6K+B5Yi457uP5rWO56CU56m25omA5pW055CG
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第2頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第3頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第4頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第5頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第6頁
fCDnp43nsbsgICAgICAgfCDmj4/ov7AgICAgICAgICAgICAgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwKfCBEaW1lciAgICAgIHwg5LqM6IGa5L2TICAgICAgICAgICB8CnwgT2xpZ29tZXIgICB8IOS9juiBmuS9kyAgICAgICAgICAgfAp8IFByb3RvZmlicmlsfCDljp/nuqTnu7QgICAgICAgICAgIHwKfCBGaWJyaWwgICAgIHwg57qk57u0ICAgICAgICAgICAgIHwKfCBBbXlsb2lkIHBsYXF1ZSB8IOa3gOeyieagt+aWkeWdlyAgICAgICB8CgrotYTmlpnmnaXmupA6IFNpZ25hbCBUcmFuc2R1Y3Rpb24gYW5kIFRhcmdldGVkIFRoZXJhcHksIGRvaTogMTAuMTAzOC9zNDEzOTItMDIzLQ==
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第7頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第8頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第9頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第10頁
fCDml7bpl7QgICAgICAgfCBnbG9iYWwgfCBVUyAgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tfC0tLS0tfAp8IFExIEZZMjAyMyAgfCAwLjcgICAgfCAwLjcgfAp8IFEyIEZZMjAyMyAgfCAyLjkgICAgfCAyLjkgfAp8IFEzIEZZMjAyMyAgfCAxMC42ICAgfCAxMC40fAp8IFE0IEZZMjAyMyAgfCAyOC4zICAgfCAyNC40fAp8IFExIEZZMjAyNCAgfCA2My4wICAgfCA0Ni4wfAoK6LWE5paZ5p2l5rqQ77yaRWlzYWnotKLmiqXvvIzlm73kv6Hor4HliLjnu4/mtY7noJTnqbbmiYDmlbTnkIY=
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第11頁
fCBGWTIwMjMgfCBGWTIwMjQgMVEgfCBGWTIwMjQgMlEgfCBGWTIwMjQgM1EgfCBGWTIwMjQgNFEgfAp8LS0tLS0tLS0tfC0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLXwKfCA0MDAgICAgIHwgMTgwMCAgICAgICB8IDM1MDAgICAgICAgfCA1MjAwICAgICAgIHwgNzAwMCAgICAgICB8CgrotYTmlpnmnaXmupDvvJpFaXNhaea8lOekuuadkOaWme+8jOWbveS/oeivgeWIuOe7j+a1jueglOeptuaJgOaVtOeQhg==
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第12頁
fCBWaXNpdHMgKHdlZWtzKSB8IFBsYWNlYm8gfCBHVi05NzEgfAp8LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS18LS0tLS0tLS18CnwgMCAgICAgICAgICAgICAgfCAtMi4wNCAgIHwgLTEuNDIgIHwKfCA0ICAgICAgICAgICAgICB8IC0yLjMyICAgfCAtMS43MCAgfAp8IDggICAgICAgICAgICAgIHwgLTIuMTkgICB8IC0xLjUwICB8CnwgMTIgICAgICAgICAgICAgfCAtMi43MCAgIHwgLTEuMTYgIHwKCui1hOaWmeadpea6kO+8mkFsemhlaW1lcidzIFJlc2VhcmNoICYgVGhlcmFweSwgZG9pOiAxMC4xMTg2L3MxMzE5NS0wMjEtMDA3OTUtNywg5Zu95L+h6K+B5Yi457uP5rWO56CU56m25omA5pW055CG
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第13頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第14頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第15頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第16頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第17頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第18頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第19頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第20頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第21頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第22頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第23頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第24頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第25頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第26頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第27頁
fCDljJblkIjniakgICAgICAgICB8IOe7k+aehOeJueW+gSAgICAgICAgICAgICAgICAgICAgICAgfAp8LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCBHYWxhbnRhbWluZSAgICB8IOWMheWQq+awp+WOn+WtkOWSjOawruWOn+WtkOeahOeOr+eKtue7k+aehCAgIHwKfCBCZW56Z2FsYW50YW1pbmV8IOWQq+acieiLr+eOr+WSjOawp+WOn+WtkOeahOe7k+aehCAgICAgICAgIHwKCui1hOaWmeadpea6kO+8mkFscGhhIENvZ25pdGlvbuWumOe9ke+8jOWbveS/oeivgeWIuOe7j+a1jueglOeptuaJgOaVtOeQhg==
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第28頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第29頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第30頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第31頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第32頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第33頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第34頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第35頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第36頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第37頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第38頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第39頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第40頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第41頁
fCDoja/niannsbvlnosgfCDpgJrnlKjlkI0v5Luj5Y+3IHwg56CU5Y+R5LyB5LiaIHwg6Z2254K5L+aKl+WOny/oja/nianorr7orqEgfCDlhajnkIPov5vluqYgfCDlhajnkIPml7bpl7QgfCDkuK3lm73ov5vluqYgfCDkuK3lm73ml7bpl7QgfAp8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8Cnwg5oqX5L2TIHwgUmVtdGVybmV0dWcgfCBFbGkgTGlsbHkgfCBOM3BHLUHOsiB8IFBoMyB8IDIwMjIuMDggfCBQaDMgfCAyMDIzLjAyIHwKfCDmipfkvZMgfCBTYWJybmV0dWcvQUNVLTE5MyB8IEFjdW1lbiB8IHNvbHVibGUgQc6yIG9saWdvbWVycyB8IFBoMi8zIHwgMjAyNC4wMyB8ICB8ICB8Cnwg5oqX5L2TIHwgQUJCVi05MTYgfCBBYmJ2aWUgfCBOM3BHLUHOsiB8IFBoMiB8IDIwMjIuMDMgfCAgfCAgfAp8IOaKl+S9kyB8IFRyb250aW5lbWF0IHwgUm9jaGUgfCBBzrIgfCBQaDEvMiB8IDIwMjAuMTEgfCAgfCAgfAp8IOaKl+S9kyB8IFNIUi0xNzA3IHwg5oGS55Ge5Yy76I2vIHwgQc6yIHwgUGgyIHwgMjAyMy4xMiB8ICB8ICB8Cnwg5oqX5L2TIHwgUFJYMDEyIHwgUHJvdGhlbmEgfCBBzrIgfCBQaDEgfCAyMDIyLjAzIHwgIHwgIHwKfCDmipfkvZMgfCBQTU4gMzEwIHwgUHJvTUlTIE5ldXJvc2NpZW5jZXMgfCBBzrIgKG9saWdvbWVyKSB8IFBoMSB8IDIwMjMuMTAgfCAgfCAgfAp8IOaKl+S9kyB8IENNMzgzIHwg5bq36K+65LqaIHwgQc6yIHwgUGgxIHwgMjAyNC4wNSB8ICB8ICB8Cnwg5oqX5L2TIHwgQUxJQS0xNzU4IHwgQWxpZGEgVGhlcmFwZXV0aWNzIHwgTjNwRy1BzrIgfCBQaDEgfCAyMDI0LjA1IHwgIHwgIHwKfCDmipfkvZMgfCBBQnZhYzQwIHwgQXJhZGlnbSBCaW90ZWNoIHwgQc6yMy00MCB8IFBoMiB8IDIwMTcuMDMgfCAgfCAgfAp8IOaKl+S9kyB8IEFDSS0yNC4wNjAgfCBBQyBJbW11bmUvVGFrZWRhIHwgQc6yMS0xNSB8IFBoMiB8IDIwMTguMDUgfCAgfCAgfAp8IOeWq+iLlyB8IFVCLTMxMSB8IFZheHhpbml0eSB8IEHOsjEtMTQgfCBQaDIgfCAyMDE1LjA5IHwgIHwgIHwKfCDnlqvoi5cgfCBBTFotMTAxIHwgQWx6aW5vdmEgfCBzb2x1YmxlIG9saWdvbWVyaWMgQc6yIHwgUGgxIHwgMjAyMS4xMCB8ICB8ICB8Cnwg55ar6IuXIHwgQVYtMTk1OUQgfCBOdXJhdmF4IHwgQc6yMS0xMSB8IFBoMSB8IDIwMjQuMDYgfCAgfCAgfAp8IOeWq+iLlyB8IEFMWi04MDEgfCBBbHpoZW9uIHwgcHJvZHJ1ZyBvZiBob21vdGF1cmluZSAo6auY54mb56O66YW4KSB8IFBoMyB8IDIwMjEuMDIgfCAgfCAgfAp8IOWwj+WIhuWtkCB8IENUMTgxMiB8IENvZ25pdGlvbiBUaGVyYXBldXRpY3MgfCBTaWdtYTItUjQgfCBQaDIgfCAyMDE4LjA0IHwgIHwgIHwKfCDlsI/liIblrZAgfCB2YW5nbHVmdXRhbnN0YXQvU0lNMDQwOCB8IFZpdm9yeW9uL+WFiOWjsOiNr+S4miB8IFFQQ1RML1FQQ1QgfCBQaDIgfCAyMDIwLjA3IHwgSU5EIHwgMjAyMi4wMiB8Cnwg5bCP5YiG5a2QIHwgQUxYLTAwMSB8IEFsbHl4IFRoZXJhcGV1dGljcy9CTVMgfCBtR2x1UjUgfCBQaDEgfCAyMDIxLjAzIHwgIHwgIHwKfCDlsI/liIblrZAgfCBSUDkwMiB8IOa2puS9s+WMu+iNryB8IEHOsuiBmumbhuaKkeWItuWJgiB8IFBoMSB8IDIwMjMuMDIgfCAgfCAgfAp8IOWwj+WIhuWtkCB8IENTNjI1MyB8IEFydGVyeSBUaGVyYXBldXRpY3MgfCBBQkNBMSAo6YCa6L+HQXBvReW9seWTjUHOsua4hemZpCkgfCBQaDEgfCAyMDIzLjA3IHwgIHwgIHwKfCDlsI/liIblrZAgfCBQUkktMDAyIHwgUHJpYXZvaWQgR21iSCB8IEHOsjQy56iz5a6a5YmCIHwgUGgxIHwgMjAyMy4xMiB8ICB8ICB8Cnwg5bCP5YiG5a2QIHwgUEs1MDEgfCBQaGFybWFLdXJlIHwgQVBQ5oqR5Yi25YmCIHwgSU5EIHwgMjAyNC4wMSB8ICB8ICB8CgrotYTmlpnmnaXmupDvvJpDbGluaWNhbFRyaWFsc++8jOWbveS/oeivgeWIuOe7j+a1jueglOeptuaJgOaVtOeQhg==
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第42頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第43頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第44頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第45頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第46頁
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
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第47頁
GV-971及安慰劑組ADAS-Cog12量表在第4/12/24/36周評分數據_第48頁
所屬報告： 醫藥生物行業創新藥盤點系列報告（19）：數十年磨一劍阿爾茨海默癥診療進入新階段-240814（50頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站